
Mochida Pharmaceutical Co., Ltd.
4534.TJPXHealthcareDrug Manufacturers - Specialty & Generic
Latest quote
¥3,265
+¥5.00 · +0.15%
4534.T company overview
Regular session · JST · Market data may be delayed.
Company profile
Company websiteEstablished in 1913 and headquartered in Tokyo, Japan, Mochida Pharmaceutical Co., Ltd. specializes in the development, manufacturing, and distribution of a wide array of medical and personal care products. Its primary offerings encompass pharmaceuticals, diagnostic solutions, and skincare lines. The company's extensive pharmaceutical portfolio includes treatments for a variety of conditions, such as cardiovascular issues, pain (analgesics), gastrointestinal ailments, neurological disorders, infections (anti-infectives), diabetes (antidiabetics), and cancer (oncological agents). Additionally, it provides hormone and biological preparations, alongside biosimilars, catering to therapeutic areas like dermatology, psychiatry, obstetrics, and gynecology. In diagnostics, Mochida produces various reagents, particularly those utilized for fertility and infertility assessments. Its skincare division features products designed for facial, body, and hair care. Beyond its existing product range, Mochida Pharmaceutical actively invests in research and development, with a specific focus on creating therapies for intractable diseases. The company has also forged strategic collaborations, including a partnership with Amarin Corporation plc for the advancement and market introduction of ethyl icosapentate products. Furthermore, it collaborates with Gene Techno Science Co., Ltd. to innovate regenerative medicine targeting rare and challenging digestive disorders, such as congenital isolated hypoganglionosis.
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- Headquarters
- JP
- CEO
- Naoyuki Mochida
- Listed since
- Jan 1, 2001
- Employees
- 1,479
Market position
- Volume
- 35K
- 0.34× average
- Average volume
- 102.19K
- Average daily volume
- Market cap
- 115.43B JPY
- Beta
- 0.36
- Market reference 1
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 104.59B JPY
- EV / EBITDA
- 7.97×
- Earnings yield
- 6.44%
- Free cash flow yield
- -8.19%
Profitability & efficiency
- Return on equity
- 5.63%
- Return on assets
- 4.33%
- Return on invested capital
- 4.63%
Financial health
- Current ratio
- 4.29×
Financial statements
Margin trends
Profitability as a percentage of reported revenue.
Income trends
Revenue
Operating income
Net income
| Metric (JPY) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 116.95B JPY | 105.16B JPY | 102.89B JPY | 103.26B JPY | 110.18B JPY |
| Cost of goods sold | 60.69B JPY | 51.37B JPY | 50.82B JPY | 48.15B JPY | 50.63B JPY |
| Gross profit | 56.26B JPY | 53.79B JPY | 52.07B JPY | 55.12B JPY | 59.55B JPY |
| Research and development | — | 11.68B JPY | 12.55B JPY | 13.28B JPY | 12.3B JPY |
| Selling, general, and administrative | 46.11B JPY | 33.99B JPY | 33.71B JPY | 33.32B JPY | 32.87B JPY |
| Operating expenses | 46.11B JPY | 45.66B JPY | 46.27B JPY | 46.61B JPY | 45.16B JPY |
| Interest income | 112M JPY | 29M JPY | 2M JPY | 2M JPY | 2M JPY |
| Interest expense | 72M JPY | 3M JPY | 2M JPY | — | — |
| Depreciation and amortization | 2.98B JPY | 2.94B JPY | 2.81B JPY | 2.67B JPY | 2.69B JPY |
| Operating income | 10.15B JPY | 8.13B JPY | 5.8B JPY | 8.51B JPY | 14.39B JPY |
| Net income | 7.9B JPY | 5.69B JPY | 4.55B JPY | 6.65B JPY | 10.57B JPY |
Company facts updated Aug 24, 2026.
Earnings
- Latest EPS result
- 89.75
EPS: actual versus estimate
Recent quarterly results
Revenue: actual versus estimate
Recent quarterly results
Corporate actions
Corporate action history
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Mar 27, 2019 | 2:1 | — | — |
Stock split | Sep 26, 2013 | 1:5 | — | — |
Effective Mar 27, 2019
2:1
Effective Sep 26, 2013
1:5
4534.T peers
ETFs holding 4534.T
Funds reporting this stock among their holdings, ordered by reported position size.
iShares Core TOPIX ETF1475.T199.19M0.01%2.89T JPY0.05%¥417.7-0.07%
Vanguard Total International Stock ETFVXUS6.17M0.00%646.2B USD0.05%$87.0899-0.71%
Vanguard FTSE Developed Markets ETFVEA4.08M0.00%315B USD0.03%$72.985-0.59%
iShares Core MSCI EAFE ETFIEFA2.77M0.00%195.14B USD0.07%$100.59-0.26%
Vanguard FTSE All-World ex-US Small-Cap ETFVSS1.63M0.01%13.6B USD0.06%$159.39-0.42%
iShares MSCI EAFE Small-Cap ETFSCZ1.47M0.01%13.28B USD0.40%$86.535-0.08%
iShares Core MSCI Total International Stock ETFIXUS1.29M0.00%60.91B USD0.07%$97.2588-0.70%
Schwab International Small-Cap Equity ETFSCHC956.2K0.02%5.73B USD0.06%$51.16-0.18%
iShares Core TOPIX ETF1475.T- Market value
- 199.19M
- Weight
- 0.01%
- AUM
- 2.89T JPY
- Expense ratio
- 0.05%
- Price / 1D
- ¥417.7-0.07%
Vanguard Total International Stock ETFVXUS- Market value
- 6.17M
- Weight
- 0.00%
- AUM
- 646.2B USD
- Expense ratio
- 0.05%
- Price / 1D
- $87.0899-0.71%
Vanguard FTSE Developed Markets ETFVEA- Market value
- 4.08M
- Weight
- 0.00%
- AUM
- 315B USD
- Expense ratio
- 0.03%
- Price / 1D
- $72.985-0.59%
iShares Core MSCI EAFE ETFIEFA- Market value
- 2.77M
- Weight
- 0.00%
- AUM
- 195.14B USD
- Expense ratio
- 0.07%
- Price / 1D
- $100.59-0.26%
Vanguard FTSE All-World ex-US Small-Cap ETFVSS- Market value
- 1.63M
- Weight
- 0.01%
- AUM
- 13.6B USD
- Expense ratio
- 0.06%
- Price / 1D
- $159.39-0.42%
iShares MSCI EAFE Small-Cap ETFSCZ- Market value
- 1.47M
- Weight
- 0.01%
- AUM
- 13.28B USD
- Expense ratio
- 0.40%
- Price / 1D
- $86.535-0.08%
iShares Core MSCI Total International Stock ETFIXUS- Market value
- 1.29M
- Weight
- 0.00%
- AUM
- 60.91B USD
- Expense ratio
- 0.07%
- Price / 1D
- $97.2588-0.70%
Schwab International Small-Cap Equity ETFSCHC- Market value
- 956.2K
- Weight
- 0.02%
- AUM
- 5.73B USD
- Expense ratio
- 0.06%
- Price / 1D
- $51.16-0.18%
Continue in GoAI
Research 4534.Tresearch.disclaimer





